|Bid||28.50 x 1000|
|Ask||31.13 x 800|
|Day's Range||29.96 - 31.12|
|52 Week Range||6.03 - 35.26|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.33|
Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.
Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.